Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
October 30 2024 - 5:00PM
Business Wire
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a
social innovation platform dedicated to accelerating promising
health innovations, today announced the hosting of an update and
Q&A session with CEO Amro Albanna this Friday, November 1,
2024, at 11:30 AM ET. This update aims to connect with our
stakeholders, including investors and the public, offering insights
into the Company’s latest developments and will address
pre-submitted questions.
This week’s session will cover:
- Aditxt Overview and Transaction Updates
- Nasdaq Compliance Update
- Q&A Segment
Participants are encouraged to engage directly by submitting
questions via email or video by October 31st, 2024, at 5:00 PM ET
to engagement@aditxt.com Registration details are available
here.
About Aditxt, Inc.
Aditxt, Inc.® is a social innovation platform dedicated to
accelerating promising health innovations. Aditxt’s ecosystem of
research institutions, industry partners, and shareholders
collaboratively drives their mission to "Make Promising Innovations
Possible Together." The innovation platform is the cornerstone of
Aditxt’s strategy, where multiple disciplines drive disruptive
growth and address significant societal challenges. Aditxt operates
a unique model that democratizes innovation, ensures every
stakeholder’s voice is heard and valued, and empowers collective
progress.
Aditxt currently operates two programs focused on immune health
and precision health. The Company plans to introduce two additional
programs dedicated to public health and women’s health. For these,
Aditxt has entered into an Arrangement Agreement with Appili
Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which
focuses on infectious diseases, and a Merger Agreement with Evofem
(OTCQB: EVFM). Each program will be designed to function
autonomously while collectively advancing Aditxt’s mission of
discovering, developing, and deploying innovative health solutions
to tackle some of the most urgent health challenges. The closing of
each of the transactions with Appili and Evofem is subject to
several conditions, including but not limited to approval of the
transactions by the respective target shareholders and Aditxt
raising sufficient capital to fund its obligations at closing. No
assurance can be provided that all of the conditions to closing
will be obtained or satisfied or that either of the transactions
will ultimately close.
For more information, www.aditxt.com.
Follow us on:
LinkedIn: https://www.linkedin.com/company/aditxt Facebook:
https://www.facebook.com/aditxtplatform/
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses, or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s ability to finance and execute its strategic M&A
initiatives; the Company’s ability to obtain the necessary funding
and partner to commence clinical trials; the Company’s intellectual
property position; the Company’s ability to develop commercial
functions; expectations regarding product launch and revenue; the
Company’s results of operations, cash needs, spending, financial
condition, liquidity, prospects, growth, and strategies; the
Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled “Risk Factors” in Aditxt’s most recent Annual Report
on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241030287839/en/
Aditxt, Inc. Investors: Jeff
Ramson, PCG Advisory, Inc. T: 646-863-6893 M: 917-912-9130
Jramson@pcgadvisory.com
Corporate Communications: Mary O’Brien Mobrien@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Dec 2023 to Dec 2024